EGFR and non-small cell lung carcinoma: Olmutinib (brand name: Olita) was developed by Hanmi Pharmaceutical Co., Ltd. and later licensed to Boehringer Ingelheim for its potential in targeting EGFR mutations in NSCLC, particularly those patients with the T790M mutation, which induces resistance against initial-generation EGFR TKIs [60].